Product Description

Ceritinib is a tyrosine kinase inhibitor (TKI) indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), demonstrating potent antitumor activity.

Screeningbio‘s NCI-H2228/Ceritinib resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Ceritinib (Zykadia) is a next-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‑positive non‑small cell lung cancer (NSCLC). It acts by binding to the ATP‑binding pocket of the ALK kinase domain, thereby blocking downstream signaling cascades including STAT3, PI3K/AKT, and MAPK pathways. This inhibition induces cell cycle arrest and apoptosis in ALK‑driven tumors, particularly in patients who have developed resistance to first‑generation ALK inhibitors such as crizotinib. Despite its initial clinical efficacy, acquired resistance inevitably emerges, limiting long‑term therapeutic benefit.

Mechanistically, ceritinib resistance arises through diverse cellular adaptations. Secondary mutations within the ALK kinase domain—such as the gatekeeper mutation L1196M, the solvent‑front mutation G1202R, and other compound mutations—reduce drug binding affinity and restore ALK signaling. Bypass pathway activation, including amplification of EGFR, KRAS mutations, or activation of c‑MET, SRC, and IGF‑1R, provides alternative survival signals independent of ALK. Upregulation of drug efflux transporters such as ABCB1 (P‑glycoprotein) and ABCG2 also contributes to decreased intracellular ceritinib accumulation. Furthermore, phenotypic changes like epithelial–mesenchymal transition (EMT) and enhanced autophagic flux have been implicated in reduced drug sensitivity.

Understanding these resistance mechanisms is essential for designing effective strategies to overcome them. Promising approaches include developing fourth‑generation ALK inhibitors active against compound mutations, combining ceritinib with inhibitors of bypass pathways (e.g., MEK, SRC, or EGFR), co‑administering efflux transporter modulators, or using patient‑derived resistant cell models to guide personalized combination therapy and sequencing of ALK inhibitors.